Platelet Biogenesis Inc. has resolved litigation against a venture capital investor that claimed it was duped by the biotech company’s fraudulent hype about a potential breakthrough platform for treating arthritis and autoimmune diseases, according to a court filing in Delaware.
Platelet and the investor, SymBiosis II LLC, docketed a joint stipulation Wednesday dropping the case from Delaware’s Chancery Court, where it began in January. The filing says they “determined to resolve this action without continued litigation” even though Platelet “disputes the allegations.”
A spokesperson for Platelet confirmed to Bloomberg Law on Thursday “that this matter has been resolved amicably” but ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.